FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 19, 2020 at 10:52 AM.

  1. #1 cafead, Nov 19, 2020 at 10:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

    article source
     
    Quote

Reply to Thread